Skip to main content
Fig. 4 | Journal of Patient-Reported Outcomes

Fig. 4

From: Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study

Fig. 4

Probability of meaningful within-patient change† in VAS score (Weeks 49–52). *P < 0.001; † ≥ 2.5-point change (improvement) for overall symptoms, nasal discharge, and facial pain VAS scores, and a ≥ 3-point change (improvement) for nasal obstruction, loss of sense of smell, and mucus in throat VAS scores. CI Confidence interval, VAS Visual analogue scale

Back to article page